Agenus Inc. - Common Stock (NQ:AGEN)

7.490 -1.240 (-14.20%)

Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Agenus Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies

June 27, 2024

From Agenus Inc.

Via Business Wire

Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors

June 17, 2024

From Agenus Inc.

Via Business Wire

Nature Medicine Reports Agenus’ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50

June 13, 2024

From Agenus

Via Business Wire

Up 40%: Is This Red-Hot Growth Stock Still a Buy? ↗

April 28, 2024

This small-cap biotech stock is surging. Time to buy?

Via The Motley Fool

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

June 05, 2024

Via Benzinga

Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

June 04, 2024

Via Benzinga

Saia, Annexon, Core Scientific And Other Big Stocks Moving Higher On Tuesday ↗

June 04, 2024

Via Benzinga

Agenus Announces Virtual Annual Shareholders Meeting

June 04, 2024

From Agenus Inc.

Via Business Wire

Medical Moonshots: 3 Biotech Stocks Set to Skyrocket ↗

May 30, 2024

Though risky, investors who buy biotech stocks watch their portfolios skyrocket when their drugs work as intended.

Via InvestorPlace

7 Biotech Stocks to Put on Your Breakthrough Radar ↗

May 27, 2024

Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance.

Via InvestorPlace

Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 24, 2024

From Agenus Inc.

Via Business Wire

Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting

May 23, 2024

From Agenus Inc.

Via Business Wire

Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

May 23, 2024

From Agenus Inc.

Via Business Wire

3 Magnificent Growth Stocks to Buy Hand Over Fist ↗

May 22, 2024

Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst.

Via The Motley Fool

Topics Economy

FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer

May 16, 2024

From Agenus Inc.

Via Business Wire

Agenus (AGEN) Q1 2024 Earnings Call Transcript ↗

May 07, 2024

AGEN earnings call for the period ending March 31, 2024.

Via The Motley Fool

Topics Earnings

AGEN Stock Earnings: Agenus Misses EPS, Misses Revenue for Q1 2024 ↗

May 07, 2024

AGEN stock results show that Agenus missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

Agenus Reports First Quarter 2024 Results

May 07, 2024

From Agenus Inc.

Via Business Wire

Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement

May 07, 2024

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 01, 2024

From Agenus Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

April 26, 2024

Via Benzinga

Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting

April 24, 2024

From Agenus Inc.

Via Business Wire

Top 2 Health Care Stocks Which Could Rescue Your Portfolio This Month ↗

April 23, 2024

Via Benzinga

Agenus to Provide First Quarter 2024 Financial Report and Corporate Update

April 23, 2024

From Agenus Inc.

Via Business Wire

Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

April 12, 2024

Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings.

Via Benzinga

Small-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom ↗

April 12, 2024

The latest Phase 1 trial results of Agenus' botensilimab and balstilimab (BOT/BAL) combination therapy for metastatic CRC showcase promising clinical activity.

Via Benzinga

Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer

April 12, 2024

From Agenus Inc.

Via Business Wire

Gold Moves Higher; Auddia Shares Surge ↗

April 08, 2024

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 0.1% on Monday. The Dow traded up 0.04% to 38,919.32 while the NASDAQ rose 0.11% to 16,266.07. The S&P 500...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Monday's Intraday Session ↗

April 08, 2024

Via Benzinga

Why Agenus Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

April 08, 2024

Shares of Agenus Inc. (NASDAQ: AGEN) fell sharply during Monday’s session. Agenus disclosed a 1-for-20 reverse stock split of common stock. Agenus Inc. (NASDAQ: AGEN) declined 17% to $0.4181 on...

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.